Literature DB >> 1730119

Survival for clinical stage I lung cancer not surgically treated. Comparison between screen-detected and symptom-detected cases. The Japanese Lung Cancer Screening Research Group.

T Sobue1, T Suzuki, M Matsuda, T Kuroishi, S Ikeda, T Naruke.   

Abstract

To assess the extent of overdiagnosis bias in lung cancer screening, clinical Stage I lung cancer cases detected by chest radiograph examination, with histologic or cytologic evidence of malignancy and not treated by surgical operation, were followed up for more than 10 years. Of 1297 screen-detected and 1297 symptom-detected cases collected from 20 institutions, 42 screen-detected and 27 symptom-detected cases satisfied the study criteria. In about half of the cases, the patients had no contraindication for surgical treatment, but they refused surgical procedure. All such patients from the screen-detected and symptom-detected groups died within 122 and 67 months, respectively, of diagnosis. Among the screen-detected and symptom-detected cases, 80% and 81%, respectively, of the patients died of lung cancer. The median survival time was 25 and 13 months for those in the screen-detected and symptom-detected groups, respectively. The difference in survival was statistically significant between the two groups, which indicated the effect of lead time and length-biased sampling. Analysis of the causes of death other than lung cancer showed that there was no difference in the observed cumulative rates of deaths of other causes between the two groups, and these figures were almost the same as those expected from the general population. This indicates that overdiagnosis bias would be minimal in screen-detected lung cancer cases detected by chest radiograph examination.

Entities:  

Mesh:

Year:  1992        PMID: 1730119     DOI: 10.1002/1097-0142(19920201)69:3<685::aid-cncr2820690315>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Screening for lung cancer: can it be cost-effective?

Authors:  O S Miettinen
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

Review 2.  Detection of early lung cancer.

Authors:  J C Porter; S G Spiro
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

3.  Unsupervised segmentation of lung fields in chest radiographs using multiresolution fractal feature vector and deformable models.

Authors:  Wen-Li Lee; Koyin Chang; Kai-Sheng Hsieh
Journal:  Med Biol Eng Comput       Date:  2015-11-03       Impact factor: 2.602

Review 4.  Recent progress in computer-aided diagnosis of lung nodules on thin-section CT.

Authors:  Qiang Li
Journal:  Comput Med Imaging Graph       Date:  2007-03-21       Impact factor: 4.790

Review 5.  Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials.

Authors:  G Wright; R L Manser; G Byrnes; D Hart; D A Campbell
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

6.  Forced vital capacity predicts long-term survival for curative-resected NSCLC.

Authors:  Xi Guo; Hongxin Cao; Jun Xu; Jianyu Yu; Chunlong Zheng; Long Meng; Jiajun Du
Journal:  Med Oncol       Date:  2014-08-07       Impact factor: 3.064

7.  Assessing the extent of non-aggressive cancer in clinically detected stage I non-small cell lung cancer.

Authors:  Minal S Kale; Keith Sigel; Grace Mhango; Juan P Wisnivesky
Journal:  Thorax       Date:  2017-10-20       Impact factor: 9.139

8.  The value of FDG-PET/CT in assessing single pulmonary nodules in patients at high risk of lung cancer.

Authors:  Olga Kagna; Anna Solomonov; Zohar Keidar; Rachel Bar-Shalom; Oren Fruchter; Mordechai Yigla; Ora Israel; Luda Guralnik
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-02-05       Impact factor: 9.236

9.  Exploring the uncertainties of early detection results: model-based interpretation of mayo lung project.

Authors:  Lu Shi; Haijun Tian; William J McCarthy; Barbara Berman; Shinyi Wu; Rob Boer
Journal:  BMC Cancer       Date:  2011-03-07       Impact factor: 4.430

10.  What is a reasonable cost to refute a preposterous hypothesis?

Authors:  A W Castleberry; F W Grannis
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.